Last reviewed · How we verify
treatment with CAZ-AVI
CAZ-AVI is a combination of ceftazidime and avibactam that works by inhibiting bacterial beta-lactamases while ceftazidime attacks the bacterial cell wall.
CAZ-AVI is a combination of ceftazidime and avibactam that works by inhibiting bacterial beta-lactamases while ceftazidime attacks the bacterial cell wall. Used for Complicated urinary tract infections (cUTI) caused by susceptible gram-negative bacteria, Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), Complicated intra-abdominal infections (cIAI).
At a glance
| Generic name | treatment with CAZ-AVI |
|---|---|
| Sponsor | Southeast University, China |
| Drug class | Beta-lactam/beta-lactamase inhibitor combination |
| Target | Bacterial penicillin-binding proteins and serine beta-lactamases |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Ceftazidime is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Avibactam is a beta-lactamase inhibitor that protects ceftazidime from degradation by serine beta-lactamases, including extended-spectrum beta-lactamases (ESBLs), AmpC beta-lactamases, and some carbapenemases. This combination restores the activity of ceftazidime against resistant gram-negative bacteria.
Approved indications
- Complicated urinary tract infections (cUTI) caused by susceptible gram-negative bacteria
- Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP)
- Complicated intra-abdominal infections (cIAI)
- Gram-negative infections in patients with limited treatment options
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Headache
- Phlebitis at infusion site
Key clinical trials
- Different Administration Regimens of CAZ-AVI in Combination With ATM for the Treatment of CR-GNB (PHASE4)
- PK/PD Relationship of CAZ/AVI and FOS in the Treatment of Patients With Infections Due to CRE
- A Combination Therapy With Ceftazidime and Fosfomycin Will be Compared to Ceftazidime Alone in Hospitalized Adult Patients With Suspected Severe Gram-negative Bacterial Infections (PHASE3)
- Clinical Study on Monitoring the Plasma Concentration of Ceftazidime-Avibactam in Critically Ill Patients
- A Multicenter Clinical Study on the Continuous vs. Intermittent Infusion of Ceftazidime-Avibactam in Critically Ill Patients With Severe Infections (PHASE4)
- Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults (PHASE4)
- PK/PD Analysis of Ceftazidime/Avibactam or Cefiderocol With or Without Fosfomycin for the Treatment of Difficult To-treat Gram-negative Infections
- Relationship Between Different Administration Regimens of Ceftazidime/Avibactam and Clinical Outcomes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- treatment with CAZ-AVI CI brief — competitive landscape report
- treatment with CAZ-AVI updates RSS · CI watch RSS
- Southeast University, China portfolio CI